Quick Answer
Chemomab Therapeutics Ltd. reported Net Income of -$8.99 million for fiscal year 2025.
Chemomab Therapeutics Ltd. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$8.99M | +35.5% |
| 2024 | -$13.95M | +42.4% |
| 2023 | -$24.22M | +12.4% |
| 2022 | -$27.65M | -121.6% |
| 2021 | -$12.48M | -109.7% |
| 2020 | -$5.95M | +78.1% |
| 2019 | -$27.12M | -96.6% |
| 2018 | -$13.80M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | -$8.75M | -71.5% | -8.3% |
| September 30, 2022 | -$8.08M | -172.2% | -30.5% |
| June 30, 2022 | -$6.19M | -123.5% | -21.3% |
| March 31, 2022 | -$5.10M | -199.5% | -72.0% |
| September 30, 2021 | -$2.97M | -142.5% | -7.1% |
| June 30, 2021 | -$2.77M | -156.2% | -62.6% |
| March 31, 2021 | -$1.70M | -0.5% | -39.2% |
| September 30, 2020 | -$1.22M | +82.9% | -13.2% |
- Chemomab Therapeutics Ltd. showed an increase of +35.5% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, Chemomab Therapeutics Ltd.’s net income has grown by 34.8% (from -$13.80 million to -$8.99 million).
- The most recent figure is from Chemomab Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: